Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 8/20 | 0.37 |
| ▸ | ITGA5 | P08648 | 7/20 | 0.37 |
| ▸ | ITGB3 | P05106 | 6/20 | 0.36 |
| ▸ | ITGAV | P06756 | 6/20 | 0.36 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.35 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.33 |
| ▸ | LSS | P48449 | 2/20 | 0.33 |
| ▸ | MDM4 | O15151 | 1/20 | 0.33 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7032406 | 0.88 | ITGB1 (0.42) | ITGB1ITGA5ITGB3ITGAVMEN1 | |
| SCHEMBL7032362 | 0.87 | CASP1 (0.41) | ITGB1ITGA5ITGB3ITGAV | |
| SCHEMBL7034074 | 0.87 | ITGB1 (0.43) | ITGB1ITGA5ITGB3ITGAV | |
| SCHEMBL7036641 | 0.87 | ITGB3 (0.39) | ITGB1ITGA5ITGB3ITGAV | |
| SCHEMBL7031372 | 0.86 | ITGB1 (0.39) | ITGB1ITGA5ITGB3ITGAVITGA4 | |
| SCHEMBL7035393 | 0.86 | KMT2A (0.45) | ITGB1ITGA5ITGB3ITGAVMEN1 | |
| SCHEMBL7383429 | 0.86 | FOLH1 (0.39) | ITGB1ITGA5ITGB3ITGAVITGA4 | |
| SCHEMBL7035368 | 0.86 | ITGB3 (0.47) | ITGB3ITGAV | |
| SCHEMBL7033711 | 0.85 | ITGB3 (0.38) | ITGB1ITGA5ITGB3ITGAVMEN1 | |
| SCHEMBL7036629 | 0.85 | EGLN2 (0.39) | ITGB1ITGA5ITGB3ITGAVMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030186967-A1 | Acylresorcinol derivatives are selective vitronectin receptor inhibitors | AMERICAN HOME PRODUCTS CORPORATION (US) | 2003-10-02 | — | — | US | claimed |
| US-20030186967-A1 | Acylresorcinol derivatives are selective vitronectin receptor inhibitors | AMERICAN HOME PRODUCTS CORPORATION (US) | 2003-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186967-A1 | Acylresorcinol derivatives are selective vitronectin receptor inhibitors | ASGR1, TEK, APLNR | ITGB1 306/4885ITGA5 450/4885ITGB3 403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.